What was the starting point? The FP7 Microbiome Landscape (2007‑2013)
The European Union’s Seventh Framework Programme (FP7) was the first large‑scale research funding scheme to treat the microbiome as a distinct scientific domain. While the term “microbiome” had already appeared in specialist journals, it was not yet a mainstream research topic. FP7 addressed this gap by creating dedicated calls that linked microbiology, ecology, bioinformatics and clinical science.
Key characteristics of the FP7 microbiome agenda were:
- Exploratory focus. Projects aimed to map microbial communities in soil, water, food and the human body without presupposing immediate applications.
- Cross‑disciplinary consortia. Grants required at least three independent organisations from different EU member states, encouraging collaboration between university labs, national research institutes and small‑to‑medium enterprises.
- Method‑development priority. Many awards funded new sequencing platforms, sample‑preservation protocols and computational pipelines that later became standard.
Examples of flagship FP7 projects include:
- MetaHIT (Metagenomics of the Human Intestinal Tract) – one of the first pan‑European attempts to catalogue gut bacteria in health and disease.
- AlgaeMicrob (Algal Microbiome Interactions) – investigated symbiotic bacteria that support algal biofuel production.
- FoodMicrobiome – explored microbial dynamics in fermented foods across the continent.
These projects generated more than 1 000 publications and set a foundation for the data standards and reference genomes that later programmes would rely on.
How did Horizon 2020 reshape the field?
When Horizon 2020 replaced FP7 in 2014, the EU moved from a largely exploratory stance to a “from bench to market” mindset. Funding calls explicitly referenced “translational microbiome research”, meaning that scientific insight should be linked to tangible outcomes such as diagnostics, therapeutics or sustainable agriculture.
Three intertwined trends defined Horizon 2020’s impact on microbiome work:
1. Emphasis on health‑related applications
Calls such as “Personalised Nutrition” and “Microbiome‑Based Therapeutics” required applicants to propose validated biomarkers, clinical trial designs or regulatory pathways. Consortia therefore included hospitals, biotech firms and regulatory experts. The resulting products ranged from probiotic formulations with strain‑level patent protection to diagnostic kits that measure specific gut metabolites.
2. Strengthening of data infrastructures
To avoid the “data silo” problem that plagued early projects, Horizon 2020 funded European Open Science Cloud (EOSC) components dedicated to microbiome datasets. The European Nucleotide Archive (ENA) and the Integrated European Long‑Read Archive (ELRA) expanded storage capacity, while the “MiKnow” platform offered uniform metadata templates for human, animal and environmental samples.
3. Integration of “One Health” concepts
The EU’s One Health policy, which recognises the interconnection between human, animal and environmental health, found a natural home in microbiome research. Projects such as “Farm2Fork” examined how farm‑level antibiotic use reshaped gut flora in livestock and, subsequently, in the surrounding ecosystem. Results fed directly into EU policy recommendations on antimicrobial stewardship.
What does the current Horizon Europe programme support?
Horizon Europe, launched in 2021, builds on its predecessor by adding two structural layers:
- Strategic pillars. “Health”, “Climate, Energy and Mobility”, and “Food, Bioeconomy and Natural Resources” each contain dedicated microbiome calls.
- Mission‑driven clusters. Eight EU missions (e.g., “Cure Cancer”, “Adaptation to Climate Change”) allow microbiome research to be positioned as a critical enabling technology.
Consequently, the scope of funded work is broader, yet more targeted. A typical Horizon Europe grant now expects a clear link to at least one of the following:
- Regulatory compliance (e.g., EU Novel Food Authority pathways).
- Standardised clinical endpoints (e.g., validated symptom scores for irritable bowel syndrome).
- Environmental impact metrics (e.g., carbon‑footprint reduction from microbiome‑enhanced bioremediation).
Because the funding amounts are larger – often exceeding €15 million per consortium – projects can include multiple phases: discovery, prototype development, pilot‑scale testing and, in some cases, early market entry.
Which research themes dominate Europe today?
Although the microbiome field is intrinsically interdisciplinary, a few themes repeatedly appear in recent calls.
Human health and disease
Research groups are focusing on:
- Microbiome‑derived metabolites as biomarkers for metabolic syndrome, neurodegenerative disease and cancer.
- Engineered live biotherapeutics that deliver therapeutic molecules directly in the gut.
- Personalised microbiome modulation – diet, pre‑biotics or phage therapy tailored to an individual’s microbial profile.
Agriculture and food security
Key projects explore:
- Soil‑microbe consortia that improve nitrogen use efficiency, reducing synthetic fertilizer demand.
- Microbial starters for fermentation that enhance nutritional quality while extending shelf‑life.
- Rapid, sequencing‑based diagnostics for plant pathogens, enabling early intervention.
Environmental sustainability
European initiatives link microbiomes to climate goals:
- Marine microbiome studies that assess carbon sequestration potential of phytoplankton‑associated bacteria.
- Waste‑to‑resource processes that use microbiota to convert organic waste into biogas or bio‑plastics.
- Bioremediation of polluted sites through engineered consortia that degrade plastics, pesticides or heavy metals.
How have standards and regulations kept pace?
The rapid expansion of microbiome research has forced EU bodies to clarify legal and technical frameworks. Three developments stand out.
EU Clinical Trial Regulation (CTR) and microbiome therapeutics
Since 2022, the CTR treats live biotherapeutic products (LBPs) as a distinct category, requiring:
- Strain‑level characterisation (whole‑genome sequencing, absence of antimicrobial resistance genes).
- Stability data under intended storage conditions.
- A risk‑assessment matrix that maps potential horizontal gene transfer events.
These requirements have pushed consortia to integrate quality‑by‑design (QbD) principles early in the research pipeline.
FAIR data principles for microbiome datasets
The European Commission has mandated that all Horizon Europe microbiome data be:
- Findable – registered in a recognised repository with persistent identifiers.
- Accessible – open under Creative Commons licences unless privacy constraints apply.
- Interoperable – annotated with controlled vocabularies such as the Minimal Information about any (x) Sequence (MIxS) standards.
- Reusable – accompanied by detailed metadata on sampling, extraction and bioinformatic pipelines.
Compliance is now checked by independent data stewards during grant reporting, ensuring that downstream researchers can reliably reuse datasets.
Food safety and novel foods
The European Food Safety Authority (EFSA) has published guidance on “microbial food cultures” that covers:
- Genetic stability of starter strains across production cycles.
- Absence of toxin‑encoding genes verified by PCR or sequencing.
- Quantitative risk assessment for allergenicity.
Project teams seeking market approval for fermented foods or probiotic supplements must submit these data alongside the typical dossier.
What tools and technologies are now standard?
Comparing the toolbox from FP7 to today shows a clear trajectory from basic amplicon sequencing to integrated multi‑omics pipelines.
- Sequencing platforms. Illumina short‑read remains common for large‑scale surveys, but Oxford Nanopore and PacBio long‑read technologies are now routine for strain‑level resolution and plasmid detection.
- Metabolomics. High‑resolution mass spectrometry coupled with stable‑isotope probing provides quantitative maps of microbe‑produced metabolites.
- Machine learning. Supervised classifiers (e.g., random forests) predict disease states from microbiome profiles; unsupervised clustering helps define community types (enterotypes, soil ecotypes).
- Synthetic biology. CRISPR‑based genome editing enables precise engineering of probiotic strains, while cell‑free systems allow rapid prototyping of microbiome‑derived enzymes.
- In‑situ monitoring. Portable nanopore sequencers and microfluidic devices allow field scientists to generate near‑real‑time taxonomic data for agriculture or environmental monitoring.
Because most EU projects involve multiple partners, shared computational environments such as the “EuroBioBank” cloud service have become crucial for reproducibility.
How does funding translate into tangible outcomes?
Since FP7, the European microbiome ecosystem has produced measurable outputs:
- Patents and spin‑offs. Over 200 patents filed for strain‑specific therapeutics, microbial enzymes for bio‑fabrication, and diagnostic kits. Notable spin‑offs include companies specialising in personalised gut‑health testing and soil‑microbe inoculants.
- Clinical guidelines. EFSA and the European Society of Gastroenterology have incorporated microbiome‑derived biomarkers into guidelines for managing inflammatory bowel disease.
- Policy influence. Horizon Europe findings informed the EU Farm to Fork Strategy, leading to a target of reducing antimicrobial use in livestock by 50 % by 2030.
- Training networks. EU‑funded PhD schools and summer schools have created a generation of scientists fluent in both wet‑lab microbiology and computational analysis.
These outcomes illustrate how a coordinated funding approach can move a field from discovery to implementation across sectors.
What challenges remain?
Even with substantial investment, several obstacles hinder rapid progress.
- Standardisation of sample handling. Differences in collection tubes, storage temperatures and DNA extraction kits still introduce batch effects that compromise cross‑study comparisons.
- Regulatory ambiguity for live biotherapeutics. While the CTR provides a baseline, national authorities sometimes apply divergent requirements, creating market entry barriers.
- Data privacy. Human microbiome data are considered “sensitive personal data” under GDPR, limiting data sharing unless robust anonymisation protocols are in place.
- Interpretation of multi‑omics. Integrating metagenomics, metatranscriptomics, metabolomics and proteomics demands sophisticated statistical frameworks that are still evolving.
Addressing these issues will likely shape the next wave of EU calls, with explicit emphasis on harmonised protocols, regulatory harmonisation and advanced bioinformatics training.
Where is the field headed in the next funding cycle?
Looking ahead, several directions appear poised to receive priority:
- Microbiome‑enabled climate mitigation. Projects that quantify greenhouse‑gas reduction from engineered soil or marine microbes align with the EU’s Green Deal.
- Precision nutrition platforms. Integrating individual microbiome profiles with dietary recommendation engines could support public‑health nutrition strategies.
- Cross‑kingdom interactions. Research on fungi‑bacteria‑plant consortia promises new biocontrol agents and resilient crops.
- Digital twins of the microbiome. Computational models that simulate community dynamics under perturbations could accelerate therapeutic design without extensive animal testing.
These trends suggest that future European programmes will continue to balance fundamental discovery with clear pathways to societal impact.
